English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Among 15,588Enterobacteriaceae isolates collected in 63 U.S. hospitals from 2012 to 2014, 2,129 (13.7%) displayed an extended-spectrum β-lactamase (ESBL) phenotype. These rates were similar over time (13.2 to 13.9%); however, differences amongEscherichia coli (12.7 and 15.1% in 2012 and 2014;P = 0.007) andKlebsiella pneumoniae (18.9 and 15.5% in 2012 and 2014;P = 0.006) were noted when comparing 2014 and 2012. Carbapenem-resistantEnterobacteriaceae (CRE) (2.3 and 1.8%) and carbapenem-resistantK. pneumoniae (6.8 and 5.1%;P = 0.003) rates were lower in 2014 than in 2012. Isolates carryingbla CTX-M-15 -like genes were stable (42.1 to 42.4%), but a decrease amongE. coli isolates (59.1 and 49.7%;P = 0.008) and an increase amongK. pneumoniae isolates (32.7 and 41.2%;P = 0.022) in 2014 were observed. Isolates carryingbla KPC (304) decreased over the years (16.5 and 10.9%;P = 0.008), mainly due to the decrease inK. pneumoniae isolates harboringbla KPC (n = 285; 35.6 and 28.4%;P = 0.041) in hospitals in the Mid-Atlantic and South Atlantic regions, where these isolates were highly prevalent during 2012 and 2013. Isolates carryingbla CMY-2- like andbla CTX-M-14- like genes increased (8.2 and 11.9% and 9.1 and 12.9%, respectively;P = 0.04 for both), and those producingbla SHV ESBL decreased (24.9 and 12.7%;P &lt; 0.001) over the studied years, due to a decreased occurrence of the enzymes amongK. pneumoniae isolates. Other enzymes were detected in smaller numbers of isolates, including fourK. pneumoniae isolates carryingbla NDM-1 metallo-β-lactamase (two in 2012 and two in 2014). Ceftazidime-avibactam, a recently approved β-lactamase inhibitor combination, was very active against the ESBL phenotype isolates (MIC50/90 , 0.12 and 1 μg/ml; 99.7% susceptible) and CRE strains (MIC50/90 , 0.5 and 2 μg/ml; 98.5% susceptible) that displayed elevated MIC values for many comparator agents. In conclusion, significant changes were noted in the frequencies of isolates harboring various β-lactamases among U.S. hospitals between 2012 and 2014 that will require continued monitoring.

antimicrobial agents and chemotherapy

Changes in the Frequencies of β-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against β-Lactamase-Producing Isolates